ImmunoPrecise Antibodies Ltd. (IPA.V)
| Previous Close | 5.31 |
| Open | 5.35 |
| Bid | 5.06 x 0 |
| Ask | 5.25 x 0 |
| Day's Range | 5.05 - 5.38 |
| 52 Week Range | 4.52 - 20.20 |
| Volume | |
| Avg. Volume | 16,419 |
| Market Cap | 100.063M |
| Beta (5Y Monthly) | -0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.78 |
| Earnings Date | Mar 15, 2022 - Mar 21, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
- Simply Wall St.
Despite currently being unprofitable, ImmunoPrecise Antibodies (CVE:IPA) has delivered a 44% return to shareholders over 3 years
ImmunoPrecise Antibodies Ltd. ( CVE:IPA ) shareholders have seen the share price descend 18% over the month. But that...
- Business Wire
IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant
DIEPENBEEK, Belgium, May 09, 2022--Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to share that IPA’s subsidiary Biostrand, a Belgian end-to-end multi-omics analysis platform provider, has received a €460,000 round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. Conditionally awarded in January this year, BioStrand recently satisfied the remaining criter
- Business Wire
IPA’s Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern
VICTORIA, British Columbia, April 20, 2022--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA) (TSXV: IPA) is pleased to share the outcome of recent laboratory data on their PolyTope® TATX-03 antibody cocktail, which demonstrates strong neutralizing activity toward the Omicron subvariant BA.2. The BA.2 pseudovirus was neutralized with a potency comparable to the previously analyzed Omicron BA.1, demonstrating ongoing and continued consistency of the cocktail to potently n
